Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer (Q64377598)

From Wikidata

Jump to navigation Jump to search

scientific article published on 03 May 2006

Language	Label	Description	Also known as
English	Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer	scientific article published on 03 May 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

David M Lubaroff

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Dev Karan

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Michael P Andrews

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Anna Acosta

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Chadi Abouassaly

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Madeva Sharma

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Arthur M Krieg

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

language of work or name

0 references

publication date

3 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

35-36

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

6155-6162

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

[Intraprostatic BCG vaccine in patients with prostatic cancer. Expression of interferon gamma and interleukin 4 (a preliminary study)]

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Gene therapy of prostate cancer: current and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Dendritic cell gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Phase I clinical trial of interleukin 2 (IL-2) gene therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Immunotherapy of tumors with vaccines based on xenogeneic homologous molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

CpG motifs in bacterial DNA and their immune effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Immunotherapeutic uses of CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

The critical role of type-1 innate and acquired immunity in tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.022

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.04.022

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16876291%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64377598&oldid=2133039341"